-transparent.png){kind=logo}
Serum concentrations of prednisolone were measured by radioimmunoassay after the administration of prednisone (10, 20, or 30 mg) by mouth to five healthy volunteers, five patients with severe chronic active liver disease (CALD), and five patients with CALD in remission induced by prednisone. Only minor differences were found between the groups and bioavailability was linearly related to the dose of prednisone (r = 0.993). After prednisone (10 mg) was given by mouth and by vein to similar groups of volunteers and 11 additional patients with CALD, bioavailability of oral prednisone approximated 100% of the intravenous dose and no differences were found in the pharmacokinetics of prednisolone. We conclude that prednisone is effectively absorbed and converted to prednisolone in health and CALD and find no pharmacological evidence that either drug would be superior to the other for treating CALD.
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
November 1975,
Gut,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
September 1977,
American journal of hospital pharmacy,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
May 1977,
Gastroenterology,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
April 1981,
Gastroenterology,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
January 1977,
The New England journal of medicine,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
January 1972,
Scandinavian journal of gastroenterology,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
January 1982,
Clinical pharmacokinetics,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
June 1982,
Liver,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
May 1997,
Harefuah,
M Uribe, and
S W Schalm, and
W H Summerskill, and
V L Go
October 1979,
Gastroenterology,
